Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB, Harrison SA, Thuluvath PJ, Goel A, Shiffman ML, Swain MG, Jones DEJ, Trivedi P, Kremer AE, Aspinall RJ, Sheridan DA, Dörffel Y, Yang K, Choi YJ, McWherter CA. Mayo MJ, et al. Among authors: levy c. Aliment Pharmacol Ther. 2024 Jan;59(2):186-200. doi: 10.1111/apt.17755. Epub 2023 Oct 30. Aliment Pharmacol Ther. 2024. PMID: 37904314
Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis.
Hirschfield GM, Liu X, Han Y, Gorlov IP, Lu Y, Xu C, Lu Y, Chen W, Juran BD, Coltescu C, Mason AL, Milkiewicz P, Myers RP, Odin JA, Luketic VA, Speiciene D, Vincent C, Levy C, Gregersen PK, Zhang J, Heathcote EJ, Lazaridis KN, Amos CI, Siminovitch KA. Hirschfield GM, et al. Among authors: levy c. Nat Genet. 2010 Aug;42(8):655-7. doi: 10.1038/ng.631. Epub 2010 Jul 18. Nat Genet. 2010. PMID: 20639879 Free PMC article.
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.
Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC, Floyd JA, Morley KI, Prati D, Lleo A, Cusi D; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium; Gershwin ME, Anderson CA, Lazaridis KN, Invernizzi P, Seldin MF, Sandford RN, Amos CI, Siminovitch KA. Cordell HJ, et al. Nat Commun. 2015 Sep 22;6:8019. doi: 10.1038/ncomms9019. Nat Commun. 2015. PMID: 26394269 Free PMC article.
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.
Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group. Hirschfield GM, et al. Among authors: levy c. Hepatology. 2016 Jul;64(1):189-99. doi: 10.1002/hep.28359. Epub 2016 Jan 14. Hepatology. 2016. PMID: 26597786 Clinical Trial.
Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis.
Weismüller TJ, Trivedi PJ, Bergquist A, Imam M, Lenzen H, Ponsioen CY, Holm K, Gotthardt D, Färkkilä MA, Marschall HU, Thorburn D, Weersma RK, Fevery J, Mueller T, Chazouillères O, Schulze K, Lazaridis KN, Almer S, Pereira SP, Levy C, Mason A, Naess S, Bowlus CL, Floreani A, Halilbasic E, Yimam KK, Milkiewicz P, Beuers U, Huynh DK, Pares A, Manser CN, Dalekos GN, Eksteen B, Invernizzi P, Berg CP, Kirchner GI, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran BD, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman RW, Karlsen TH, Schrumpf E, Strassburg CP, Manns MP, Lindor KD, Hirschfield GM, Hansen BE, Boberg KM; International PSC Study Group. Weismüller TJ, et al. Among authors: levy c. Gastroenterology. 2017 Jun;152(8):1975-1984.e8. doi: 10.1053/j.gastro.2017.02.038. Epub 2017 Mar 6. Gastroenterology. 2017. PMID: 28274849 Free PMC article.
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM. Jones D, et al. Among authors: levy c. Lancet Gastroenterol Hepatol. 2017 Oct;2(10):716-726. doi: 10.1016/S2468-1253(17)30246-7. Epub 2017 Aug 14. Lancet Gastroenterol Hepatol. 2017. PMID: 28818518 Clinical Trial.
Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.
Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Goldberg DS, et al. Among authors: levy c. Clin Gastroenterol Hepatol. 2018 Apr;16(4):591-593. doi: 10.1016/j.cgh.2017.10.028. Epub 2017 Nov 2. Clin Gastroenterol Hepatol. 2018. PMID: 29102704 Free PMC article. No abstract available.
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.
Younossi ZM, Afendy A, Stepanova M, Racila A, Nader F, Gomel R, Safer R, Lenderking WR, Skalicky A, Kleinman L, Myers RP, Subramanian GM, McHutchison JG, Levy C, Bowlus CL, Kowdley K, Muir AJ. Younossi ZM, et al. Among authors: levy c. Hepatology. 2018 Jul;68(1):155-165. doi: 10.1002/hep.29664. Epub 2018 May 10. Hepatology. 2018. PMID: 29152767
1,874 results